Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fampridine for functional impairment and fatigue in CIDP
ACTRN12611000800921Phase 2Not yet recruiting
- Sponsor
- University of New South Wales
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of dalfampridine in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by University of New South Wales. Primary endpoint: Six-minute walk test. Planned start Aug 2011; status: not yet recruiting.
02
Drugs
dalfampridine
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on ACTRN12611000800921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000800921.